ReviewCureus2025
Comparative Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-Like Peptide-1 Receptor Agonists in Reducing Cardiovascular Events in Patients With Type 2 Diabetes.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Treatment outcomes and safety profile of SGLT2 inhibitors versus GLP-1 agonists in type 2 diabetes mellitus : Systematic review of real-world observational studies.Wiener medizinische Wochenschrift (1946) · 2026Pooled it
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One of the primary causes of death and morbidity among individuals with type 2 diabetes mellitus (T2DM) is stroke. Despite their well-established cardiovascular advantages, there is insufficient data to determine how well sodium-glucose cotransporter-2 (SGLT2) inhibitors (SGLT2i) and glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) prevent strokes. The research conducted a systematic review and performed a meta-analysis to assess the comparative effectiveness of SGLT2i versus GLP-1 RAs for preventing stroke incidents in T2DM patients. From 2020 to 2025, the study searched PubMed, Embase, and Web of Science following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. Only observational, retrospective, and cohort studies comparing the outcomes of stroke by SGLT2i and GLP-1 RA were included in the study. For risk of bias assessment Newcastle Ottawa Scale (Version 2011) was used. For the meta-analysis, random effects methodology was used to analyze the hazard ratio (HR) with 95% CIs. The study used heterogeneity analysis in conjunction with sensitivity analyses. Eleven studies (with a total of over 500,000 participants) were included. The pooled HR for stroke was 0.92 (95% CI: 0.83-1.02), suggesting that SGLT2i and GLP-1 RA did not significantly differ from one another. Low to moderate heterogeneity was present (I
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.